The futility of current approaches to chondroprotection.
Felson
David T
DT
Boston University School of Medicine, and Children's Hospital-Boston, Harvard Medical School, Boston, Massachusetts 02118, USA. dfelson@u.edu
Kim
Young-jo
YJ
D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D002358:Cartilage, Articular / Q000378:metabolism / Q000473:pathology; D019902:Chondrocytes / Q000378:metabolism / Q000473:pathology; D004318:Doxycycline / Q000627:therapeutic use; D012968:Etidronic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use; D006801:Humans; D010003:Osteoarthritis / Q000188:drug therapy* / Q000473:pathology / Q000517:prevention & control*; D010146:Pain / Q000209:etiology / Q000517:prevention & control; D000068296:Risedronic Acid
D000900:Anti-Bacterial Agents; D050071:Bone Density Conservation Agents; D000068296:Risedronic Acid; D012968:Etidronic Acid; D004318:Doxycycline